Alert detail
LCD L38835: MolDX: Minimal Residual Disease Testing for Cancer — WPS
What changed
New LCD requires billing team review.
Who’s affected: Oncology billing teams · Effective: October 30, 2025
Affected codes
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 27 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.